Structure-activity relationships of the sustained effects of adenosine A2A receptor agonists driven by slow dissociation kinetics

Molecular Pharmacology

Volumn 91, Issue 1, 2017, Pages 25-38

  Hothersall, J Daniel ^a   Guo, Dong ^c   Sarda, Sunil ^a   Sheppard, Robert J ^a   Chen, Hongming ^b   Keur, Wesley ^c   Waring, Michael J ^a   IJzerman, Adriaan P ^c   Hill, Stephen J ^d   Dale, Ian L ^a   Rawlins, Philip B ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ANILINOADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR AGONIST; OTSUKA 3; R PIA; UK 432097; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR;

ANIMAL CELL; ARTICLE; ARTIFICIAL MEMBRANE; BINDING KINETICS; BINDING SITE; CAMP ASSAY; CHO CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG ANTAGONISM; DRUG EFFICACY; EC90; FEMALE; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SH-SY5Y CELL LINE; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL MEMBRANE; CHEMISTRY; CRICETULUS; DRUG EFFECTS; GENETIC PROCEDURES; HAMSTER; HEK293 CELL LINE; HUMAN; KINETICS; METABOLISM; RADIOASSAY; TIME FACTOR; TUMOR CELL LINE;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; KINETICS; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 85006307700     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.105551     Document Type: Article

References (44)

1. Abbracchio MP, Fogliatto G, Paoletti A.M., Rovati GE, and Cattabeni F (1992) Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors. Eur J Pharmacol 227: 317-324.
2. Adami M, Bertorelli R, Ferri N., Foddi MC, and Ongini E (1995) Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol 294: 383-389.
3. Andreassen KV, Hjuler ST, Furness S.G., Sexton PM, Christopoulos A, Nosjean O, Karsdal M.A., and Henriksen K (2014) Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS One 9:e92042.
4. Åstrand ABM, Lamm Bergström E, Zhang H, Börjesson L, Söderdahl T, Wingren C, Jansson A-H, Smailagic A, Johansson C, Bladh H, et al. (2015) The discovery of a selective and potent A2a agonist with extended lung retention. Pharmacol Res Perspect 3:e00134.
5. Austin RP, Barton P, Bonnert R.V., Brown RC, Cage PA, Cheshire DR, Davis A.M., Dougall IG, Ince F, Pairaudeau G, et al (2003) QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. J Med Chem 46: 3210-3220.
6. Baines AE, Corrêa SA, Irving A.J., and Frenguelli BG (2011) Differential trafficking of adenosine receptors in hippocampal neurons monitored using GFP- and superecliptic pHluorin-tagged receptors. Neuropharmacology 61:1-11.
7. Bridges AJ, Moos WH, Szotek D.L., Trivedi BK, Bristol JA, Heffner TG, Bruns R.F., and Downs DA (1987) N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J Med Chem 30:1709-1711.
8. Cerqueira MD (2004) The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol 94: 33D-42D.
9. Charalambous C, Gsandtner I, Keuerleber S., Milan-Lobo L, Kudlacek O, Freissmuth M., and Zezula J (2008) Restricted collision coupling of the A2A receptor revisited: evidence for physical separation of two signaling cascades. J Biol Chem 283: 9276-9288.
10. Chen JF, Eltzschig HK, and Fredholm BB (2013) Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 12:265-286.
11. Chern Y, Chiou JY, Lai H.L., and Tsai MH (1995) Regulation of adenylyl cyclase type VI activity during desensitization of the A2a adenosine receptor-mediated cyclic AMP response: role for protein phosphatase 2A. Mol Pharmacol 48:1-8.
12. Chern Y, Lai HL, Fong J.C., and Liang Y (1993) Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol Pharmacol 44:950-958.
13. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
14. de Lera Ruiz M, Lim YH, and Zheng J (2014) Adenosine A2A receptor as a drug discovery target. J Med Chem 57:3623-3650.
15. Deflorian F, Kumar TS, Phan K, Gao Z.G., Xu F., Wu H, Katritch V, Stevens R.C., and Jacobson KA (2012) Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound AzA adenosine receptor. J Med Chem 55:538-552.
16. Ferrandon S, Feinstein TN, Castro M, Wang B., Bouley R, Potts JT, Gardella T.J., and Vilardaga JP (2009) Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 5:734-742.
17. Field JJ, Lin G, Okam M.M., Majerus E., Keefer J, Onyekwere O, Ross A., Campigotto F, Neuberg D, Linden J., et al. (2013) Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood 121:3329-3334.
18. Gao ZG and Jacobson KA (2011) Emerging adenosine receptor agonists: an update. Expert Opin Emerg Drugs 16:597-602.
19. Gnad T, Scheibler S, von Kügelgen I, Scheele C, Kilic A, Glöde A, Hoffmann LS, Reverte-Salisa L, Horn P, Mutlu S, et al. (2014) Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 516: 395-399.
20. Guo D, Hillger JM, Ijzerman A.P., and Heitman LH (2014) Drug-target residence time-a case for G protein-coupled receptors. Med Res Rev 34:856-892.
21. Guo D, Mulder-Krieger T, IJzerman A.P., and Heitman LH (2012) Functional efficacy of adenosine AzA receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 166:1846-1859.
22. Guo D, van Dorp EJ, Mulder-Krieger T, van Veldhoven JP, Brussee J, Ijzerman AP, and Heitman LH (2013) Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen 18:309-320.
23. Haskell-Luevano C., Miwa H, Dickinson C., Hadley ME, Hruby VJ, Yamada T, and Gantz I (1996) Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R. J Med Chem 39: 432-435.
24. Hothersall JD, Bussey CE, Brown A.J., Scott JS, Dale I, and Rawlins P (2015) Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur J Pharmacol 762:430-442.
25. Hothersall JD, Brown AJ, Dale I, and Rawlins P (2016) Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses? Drug Discov Today 21:90-96.
26. Koshiba M, Kojima H, Huang S., Apasov S, and Sitkovsky MV (1997) Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 272:25881-25889.
27. Lebon G, Edwards PC, Leslie A.G., and Tate CG (2015) Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. Mol Pharmacol 87: 907-915.
28. Lebon G, Warne T, Edwards P.C., Bennett K., Langmead CJ, Leslie AG, and Tate CG (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-525.
29. Lee JY and Lyman E (2012) Agonist dynamics and conformational selection during microsecond simulations of the A(2A) adenosine receptor. Biophys J 102: 2114-2120.
30. Mantell S, Jones R, and Trevethick M (2010) Design and application of locally delivered agonists of the adenosine A(2A) receptor. Expert Rev Clin Pharmacol 3: 55-72.
31. Marumoto R, Yoshioka Y, Honjo M., and Kawazoe K (1974), inventors, Takeda Chemical Industries Limited, assignee. 2,6-diaminonebularinderivate 2,6-diaminonebularinderivate. Patent DE2359536 A1. 1973 Nov 29.
32. Niiya K, Jacobson KA, Silvia S.K., and Olsson RA (1993) Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 347:521-526.
33. Nishiyama K and Hirai K (2015) In vitro comparison of duration of action of melatonin agonists on melatonin MT receptor: possible link between duration of action and dissociation rate from receptor. Eur J Pharmacol 757:42-52.
34. Ong S, Liu H, Qiu X., Bhat G, and Pidgeon C (1995) Membrane partition coefficients chromatographically measured using immobilized artificial membrane surfaces. Anal Chem 67:755-762.
35. Palmer TM, Gettys TW, Jacobson K.A., and Stiles GL (1994) Desensitization of the canine A2a adenosine receptor: delineation of multiple processes. Mol Pharmacol 45:1082-1094.
36. Palmgren JJ, Monkkonen J, Korjamo T., Hassinen A, and Auriola S (2006) Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 64: 369-378.
37. Pidgeon C, Ong S, Liu H., Qiu X, Pidgeon M, Dantzig A.H., Munroe J., Hornback WJ, Kasher JS, Glunz L, et al (1995) IAM chromatography: an in vitro screen for predicting drug membrane permeability. J Med Chem 38:590-594.
38. Sato N, Yuki Y, Shinohara H., Takeji Y, Ito K, Michikami D., Hino K, and Yamazaki H (2010) inventors, Otsuka Pharmaceutical Co Ltd, assignee. A novel cyanopyrimidine derivative. Patent WO/2010/090299. 2010 Dec 8.
39. Sykes DA, Parry C, Reilly J., Wright P, Fairhurst RA, and Charlton SJ (2014) Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the b2-adrenoceptor. Mol Pharmacol 85:608-617.
40. Teschemacher A and Lemoine H (1999) Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 288:1084-1092.
41. Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488-508.
42. Wennerberg M, Balendran A, Clapham J.C., and Vauquelin G (2010) Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptorexpressing cells. Fundam Clin Pharmacol 24:181-187.
43. Xu F, Wu H, Katritch V., Han GW, Jacobson KA, Gao ZG, Cherezov V, and Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327.
44. Zezula J and Freissmuth M (2008) The A(2A)-adenosine receptor: a GPCR with unique features? Br J Pharmacol 153 (Suppl 1):S184-S190.